Core Viewpoint - Incyte's annual revenue forecast is below Wall Street expectations, raising concerns about the company's ability to offset the impact of the upcoming patent expiration of its best-selling drug, Jakafi [1][2][3] Revenue Forecast - Incyte expects revenue in 2026 to be between $4.77 billion and $4.94 billion, significantly lower than the analyst average estimate of $5.52 billion [3] - The weak forecast highlights the pressure on Opzelura, which is expected to generate revenue of $750 million to $790 million in 2026, below the analyst estimate of $801.5 million [3] Drug Performance - Opzelura's sales surged by 28% to $207.3 million in the fourth quarter, exceeding the expected $195.6 million, yet the company remains cautious about future projections [3] - Jakafi, Incyte's flagship drug for treating blood cancers, is projected to have sales of $3.22 billion to $3.27 billion in 2026, higher than the analyst estimate of $3.09 billion [4] Earnings and Milestones - In the fourth quarter, Jakafi's sales grew by 7% to $828.2 million, surpassing market expectations [5] - Incyte reported adjusted earnings per share of $1.80, below the analyst estimate of $1.93, with total revenue reaching $1.51 billion, exceeding the expected $1.35 billion due to a $100 million milestone payment [5]

Core Insights - Novartis has initiated a wave of acquisitions this year, with a focus on enhancing its drug pipeline and compensating for revenue declines from key therapies due to patent expirations [1][2] - The company reported a 6% increase in operating profit, reaching $5.46 billion in Q3, slightly above analyst expectations of $5.4 billion [1] - Q3 revenue was $13.91 billion, representing an 8.4% year-over-year growth, exceeding forecasts, while adjusted EPS was $2.25, falling short of expectations by $0.06 [1] Financial Performance - Novartis' Q3 operating profit adjusted for special items increased to $5.46 billion, surpassing analyst expectations [1] - The company has raised its annual performance outlook twice this year, maintaining its 2025 financial guidance with projected sales growth in the "mid-high single digits" and adjusted operating profit growth in the "low double digits" [1] Product Performance - The heart drug Entresto, which lost patent protection this year, generated $1.88 billion in sales during Q3, with total sales expected to reach $7.82 billion globally in 2024 [1] - Analysts had anticipated Q3 sales for Entresto to be $1.77 billion [1] - The psoriasis treatment drug Cosentyx faced competition from AbbVie's Bimzelx, with sales remaining flat at $1.7 billion year-over-year [2] - The breast cancer drug Kisqali, launched last year, achieved sales of $1.33 billion [2] Acquisition Strategy - Novartis is actively pursuing acquisitions and licensing deals valued at $30 billion, including a $12 billion acquisition of U.S. biotech company Avidity [1]